NAT2 rs1801280: Understanding Your Acetylator Status
The rs1801280 variant in the NAT2 gene is a well-studied genetic marker that influences an individual's ability to metabolize certain drugs and chemicals. It is primarily associated with the 'slow acetylator' phenotype, which can affect how quickly the body clears medications such as isoniazid.
What each genotype means
Normal enzyme activity
This genotype is associated with the rapid or normal acetylator phenotype for the NAT2 enzyme. Individuals with this profile typically metabolize drugs like isoniazid at a standard rate, though overall acetylator status is determined by a combination of multiple genetic variants. Please discuss your medication dosing and potential side effects with your clinician or pharmacist.
Carried by approximately 38% of the total U.S. population, with frequencies varying significantly by ancestry.
Intermediate enzyme activity
This genotype represents a heterozygous state that often contributes to an intermediate acetylator phenotype. Because NAT2 activity is influenced by several different genetic markers, this result should be viewed as one part of your overall metabolic profile. Consult your healthcare provider or pharmacist regarding how this may influence your response to specific medications.
This is the most common genotype for this variant, found in roughly 46% of the total U.S. population.
Reduced enzyme activity
This genotype is a primary marker associated with the slow acetylator phenotype, which can lead to slower clearance of certain drugs such as isoniazid. Being a slow acetylator may increase the risk of drug-induced side effects or toxicity in some clinical contexts. Always consult your clinician or pharmacist to review your medication plan and ensure appropriate dosing.
Carried by approximately 16% of the total U.S. population, though prevalence is highly variable across different global populations.
What is the rs1801280 Variant?
The rs1801280 variant, often referred to as the 341T>C polymorphism, is a specific change in the DNA sequence of the NAT2 gene. Located on chromosome 8, this variant involves the substitution of a thymine (T) base with a cytosine (C) base. This change results in an amino acid substitution in the resulting protein, where isoleucine is replaced by threonine at position 114. This structural alteration is a hallmark of the NAT2*5 allele group. Because this change occurs within the coding region of the gene, it can significantly impact the function of the enzyme the gene produces. Scientists track this specific SNP because it serves as a reliable indicator for predicting how an individual might process various substances, including therapeutic drugs and environmental compounds.
The Role of the NAT2 Gene
The NAT2 gene encodes the enzyme arylamine N-acetyltransferase 2. This enzyme plays a critical role in the body's detoxification and metabolism pathways by catalyzing the transfer of an acetyl group to various arylamine and hydrazine compounds. This process, known as acetylation, is essential for deactivating certain drugs and carcinogens so they can be safely excreted from the body. Humans are categorized into different acetylator phenotypes—rapid, intermediate, or slow—based on the efficiency of their NAT2 enzymes. Those with 'slow' acetylation status process these compounds more gradually, which can lead to higher concentrations of the drug remaining in the bloodstream for longer periods. This biological variation is a central focus of pharmacogenomics, the study of how genes affect a person's response to medications.
Research and Clinical Associations
Research has consistently linked the rs1801280 variant to the slow acetylator phenotype. This is particularly relevant in the context of tuberculosis treatment, where the drug isoniazid is commonly used. Studies have shown that individuals who are slow acetylators may be at a higher risk for drug-induced liver injury (DILI) when taking isoniazid, as the drug remains in their system longer. The evidence for this association is considered moderate to strong in the scientific literature. While this variant is a primary marker, it is often analyzed alongside other NAT2 SNPs to provide a more complete picture of an individual's metabolic profile. It is important to note that while genetic associations are well-documented, they are only one factor in how a patient responds to treatment; clinical factors like age, liver health, and other medications also play significant roles.
Population Frequency
The frequency of the rs1801280 variant varies significantly across different global populations. Because NAT2 polymorphisms are highly diverse, the prevalence of the slow acetylator phenotype differs between ethnic and geographic groups. In some populations, the variant is quite common, while in others, it is relatively rare. This high level of haplotype diversity means that genetic testing results for NAT2 can have very different implications depending on an individual's ancestry. Researchers continue to study these frequency patterns to better understand how genetic background influences drug safety and efficacy on a global scale.
What You Can Do With This Information
Understanding your genetic profile regarding NAT2 can be a valuable tool for personal health management, but it should never be used to make independent medical decisions. If you have information about your NAT2 genotype, the most important step is to share it with your healthcare provider or a clinical pharmacist. They can interpret these results in the context of your overall health, current medications, and medical history. Never stop or change the dosage of a prescribed medication based on genetic test results without consulting your doctor. Genetic information is meant to facilitate a conversation with your medical team, helping them tailor treatment plans to your specific needs and potentially reducing the risk of adverse drug reactions.
How common is this variant?
The frequency of the rs1801280 variant is highly variable across global populations, with slow acetylator phenotypes being common in many diverse ethnic groups.
Frequently asked questions
What does it mean to be a 'slow acetylator'?
Being a slow acetylator means your body produces a version of the NAT2 enzyme that processes certain drugs and chemicals more slowly than average. This can lead to higher levels of these substances in your blood, which may increase the risk of side effects.
Does having the CC genotype mean I will have a bad reaction to medication?
Not necessarily. While the CC genotype is associated with slower metabolism, it is only one factor in how your body responds to a drug. Many other variables, including your overall health and other medications you take, also influence your risk.
Should I get tested for NAT2 variants?
Genetic testing for NAT2 is generally not performed for the general population. It is usually only considered in specific clinical contexts, such as when a doctor needs to optimize a treatment plan for a patient taking drugs known to be affected by NAT2 metabolism.
Can I change my acetylator status?
No, your acetylator status is determined by your genetics and cannot be changed. However, knowing your status can help your doctor adjust your medication dosages or choose alternative treatments to ensure your safety.
Sources & further reading
Educational information only, last refreshed 9/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1801280?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in NAT2
Coding variant c.481C>T (p.Leu161Leu) serving as a diagnostic marker for several NAT2 slow acetylator haplotypes, including *5.
Coding variant c.857G>A (p.Gly286Glu) defining the NAT2*14 allele (often associated with slow acetylation).
Synonymous variant (282C>T) associated with the NAT2*6 allele, contributing to slow acetylator status.
Missense variant (590G>A) defining the NAT2*6A allele, associated with slow acetylator phenotype.
Synonymous polymorphism (857G>A) representing the defining mutation of the slow acetylator NAT2*7 allele.
This variant (c.590G>A, p.Arg197Gln) is a well-characterized slow acetylator allele in the NAT2 gene, influencing the metabolism of drugs like isoniazid.